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Resumo 
 
 A hipertensão essencial é uma condição multifatorial e poligénica fortemente 
associada ao consumo excessivo de sal e à desregulação da absorção de sódio. A cínase 
1 induzida pelo sal (salt-inducible kinase 1 – SIK1), uma cínase da serina/treonina, é parte 
de uma rede intracelular de sinalização ao sódio que controla o transporte ativo deste ião 
através da regulação da atividade da bomba sódio-potássio (Na+-K+-ATPase), tendo sido 
identificada como um fator determinante na regulação da tensão arterial. Recentemente, 
foi demonstrado que a perda da SIK1 despoleta uma subida da tensão arterial em ratos 
submetidos a dieta hipersalina. No presente trabalho, o papel da SIK1 no desenvolvimento 
da hipertensão sensível ao sal foi adicionalmente explorado. Num conjunto específico de 
experiências, foi dado um primeiro passo na investigação da influência da SIK1 sobre a 
absorção de sódio no trato gastrointestinal, com foco na caracterização de mecanismos 
de transporte iónico intestinal potencialmente regulados por esta cínase, tais como o 
acoplamento funcional entre a bomba sódio-potássio e as correntes de potássio 
basolaterais (pump-leak coupling). Foram registadas as alterações no potencial de 
membrana após a exposição de células a fármacos conhecidos por abrir ou fechar os 
canais de potássio sensíveis ao ATP, tendo também sido avaliados os efeitos do 
tratamento com dexametasona sobre a condutância basolateral de potássio e sobre a 
expressão e atividade da bomba sódio-potássio. Os nossos resultados demonstram que 
a dexametasona causa uma modulação dependente da dose nas correntes de potássio 
basolaterais, não associada à sobre-expressão da bomba sódio-potássio e provavelmente 
secundária ao aumento da atividade desta enzima, em consequência do seu acoplamento 
funcional aos canais de potássio sensíveis ao ATP. Além disso, o nosso estudo descreve 
pela primeira vez uma aumento da expressão da bomba sódio-potássio em células 
epiteliais intestinais tratadas com concentrações superiores de dexametasona. 
 Abstract 
Essential hypertension is a multifactorial and polygenetic condition strongly associated to 
high salt intake and sodium absorption dysregulation. Salt-inducible kinase 1 (SIK1), a sucrose 
nonfermenting-1-related serine/threonine kinase, is part of a cell sodium-sensing network that 
controls active sodium transport by regulating Na+-K+-ATPase activity and has been established as 
a key determinant in blood pressure regulation. Recently, loss of SIK1 has been shown to trigger a 
blood pressure rise in mice under chronic high salt intake. In the present work, we further explored 
the role of salt-inducible kinase 1 in sodium-sensible hypertension development. In a particular set 
of experiments, we took a first step in investigating the influence of SIK1 over transcellular sodium 
transport in the gastrointestinal tract, focusing on the characterization of intestinal ion transport 
mechanisms that are potentially under the regulation of SIK1 such as the pump-leak coupling 
between Na+-K+-ATPase and basolateral K+ currents. Changes in membrane potential were 
examined after exposure of cells to drugs known to block or open ATP-sensitive K+ channels and 
the effects of dexamethasone treatment on basolateral K+ conductance and Na+-K+-ATPase protein 
expression and activity were assessed. Our results demonstrate that dexamethasone causes a 
concentration-dependent modulation of basolateral K+ currents that is independent of Na+-K+-
ATPase protein overexpression and most likely secondary to increased NKA activity, as a result of 
the functional coupling between Na+-K+-ATPase and KATP channels. Furthermore, we also report for 
the first time that dexamethasone induces Na+-K+-ATPase upregulation in intestinal epithelial cells 
at higher treatment concentrations. 
 
Keywords 
gastrointestinal tract, hypertension, pump-leak coupling, SIK1, transcellular sodium transport 
  
 General Introduction 
Animal cells are highly permeable to water[1]. Any imbalance in intracellular or 
extracellular osmolarity is accompanied by a respective water movement across cell membrane 
and subsequent alterations in cell volume[2]. A number of volume regulatory mechanisms to avoid 
excessive variations in cell volume have been described, in particular ion transport across the cell 
membrane[2]. The ability to maintain a tightly regulated cell volume is dependent of the adequate 
ionic composition of the intracellular milieu in response to variations in the composition of the 
extracellular compartment[3]. Sodium is the most important determinant of water content in the 
body compartments, dragging water across membranes by osmolar differences[3]. In fact, sodium 
misdistribution can elicit abnormal water accumulation, leading to intra- and extracellular edema, 
hypervolemia and increased blood pressure, as occurs in patients with sodium-sensitive 
hypertension[4]. In order to control the water-attracting power of sodium and maintain 
homeostasis, cells compensate by actively pumping this ion towards the extracellular milieu[5], 
with water following isosmotically[6]. The major determinant of intracellular sodium 
concentration and the primary cell volume regulator is the plasma membrane sodium-and 
potassium-activated adenosine triphosphatase (Na+-K+-ATPase)[5]. 
The Na+-K+-ATPase (NKA) is a transmembrane heterodimer protein consisting of a 
catalytic a-subunit and a highly glycosylated b-subunit required for its integration into the plasma 
membrane and enzyme activity[7]. By using the energy-rich phosphate bound of a single ATP 
molecule,  three sodium ions (Na+) are actively translocated outward against two potassium ions 
(K+) inward[8], thus establishing an electrochemical gradient across the plasma membrane[5, 7], 
which is necessary for cardiac and vascular contractility, neural transmission and transepithelial 
transport of solutes[7]. Therefore, Na+-K+-ATPase dictates active sodium transport and related vital 
functions[6], and is target of numerous regulatory mechanisms in response to changing cell 
requirements[5]. In transporting epithelia, phosphorylation of the Na+-K+-ATPase a-subunit has 
been associated with a reduction in active cell sodium transport, whereas dephosphorylation has 
been suggested to increase NKA catalytic activity in response to physiological or pharmacological 
stimuli[3, 9-11]. Many described effectors are known to physically interact with sodium pump 
subunits after sensing small increases in intracellular sodium[6], regulating its activity, trafficking 
 and signaling (Na+-K+-ATPase-regulatory complex)[12-18] – one recently identified molecule of this 
system is salt-inducible kinase 1 (SIK1)[6]. 
Salt-inducible kinase 1 (SIK1) was first identified in the adrenal cortex of rats receiving a 
sodium-enriched diet and interpreted as an important component in the adrenocortical response 
to high plasma Na+, K+, ACTH or stress[19]. This molecule was later revealed to be part of a cell 
sodium-sensing network and described as a sucrose nonfermenting-1-related serine/threonine 
kinase that regulates NKA catalytic activity by sensing changes in intracellular sodium 
concentration and eliciting a signaling cascade that adjusts sodium extrusion[3, 6]. Accordingly, 
increased intracellular sodium fuels the sodium-calcium exchange system (NCE1), prompting 
entrance of calcium and activation of SIK1 (Thr-322 phosphorylation) by calcium calmodulin-
dependent kinase (CaMK1)[6]. SIK1 activation results in dephosphorylation of Na+-K+-ATPase a-
subunit and increase of its maximal sodium pumping capacity via Protein Phosphatase 2A (PPA2) 
activation[6, 7]. Conversely, lack of salt-inducible kinase 1 is associated with increased inactivation 
and endocytosis of Na+-K+-ATPase molecules, resulting in a reduction of its activity and protein 
expression[6]. SIK1 is involved in short-term modulation of the activity of a selected pool of NKA 
molecules that can be rapidly activated for quick adjustments in sodium transport, and does not 
affect the basal activity responsible for the housekeeping role of the sodium pump[6]. Along with 
sodium-dependent signals, SIK network has been described to mediate sodium-independent 
signals in the modulation of active sodium transport such as dopamine, angiotensin and 
aldosterone, as well as being involved in mechanisms independent of ion gradient changes such as 
insulin action, glucose homeostasis, adipocyte energy metabolism[3, 20-27], steroid synthesis[19], 
cardiomyogenesis[28, 29], gene expression and transcription[30], cell polarity, intracellular 
junction stability and apoptosis[31-33]. Notably, salt-inducible kinase 1 has been recognized as an 
important factor in blood pressure regulation via distinct pathways. 
Essential hypertension is a multifactorial and polygenetic condition strongly associated to 
high salt intake and abnormal regulation of renal sodium transport[34, 35]. Indeed, high dietary 
salt leads to a rise in blood pressure, left cardiac ventricular mass and arterial thickness and 
stiffness[35, 36]. In the renal proximal tubule, sodium uptake is driven by the sodium gradient 
established by the Na+-K+-ATPase units located at basolateral membrane[7]. Since salt-inducible 
 kinase 1 participates in the regulation of NKA activity under sodium stress conditions, it has been 
assumed that elevated basal SIK1 activity in renal epithelial cells could elicit a sustained increase 
in sodium reabsorption by the kidney, leading to plasma volume expansion and high blood 
pressure[35]. Additionally, since SIK1 has also been identified in vascular smooth muscle cells 
(VSMCs) and endothelial cells[37], it has been suggested that SIK1 could also comprise a major 
determinant in the regulation of vascular tone and development of hypertension through its 
influence on NKA activity in VSMCs upon variations in salt intake[37]. Recently, a single nucleotide 
polymorphism in the coding region of the human SIK1 gene (HapMap rs3746951) resulting in the 
substitution of glycine to serine (15Gly®Ser) in salt-inducible kinase 1 protein has been associated 
with lower blood pressure and decreased left ventricular mass, a robust marker of long-term blood 
pressure load[37]. However, this SIK1-15Ser variant strongly relates with significantly increased 
basal SIK1 activity[37], and a drop in sodium-calcium exchange and calcium delivery to the 
contractile apparatus secondary to increased Na+-K+-ATPase activity could in part explain the 
potential role of increased vascular SIK1 activity on vascular tone relaxation[38]. Moreover, it has 
been demonstrated in sik1-/- mice that loss of salt-induced kinase 1 induces high blood pressure 
and vascular remodeling processes such as dysregulated collagen synthesis and increased 
contractile phenotype of vascular smooth muscle cells secondary to increased endothelial 
production of  TGF-b1, with no observed differences in renal function[39]. Therefore, it has been 
established that lack of SIK1 is a precipitant factor in the development of sodium-sensible 
hypertension due to compromised maintenance of a relaxed vascular tone under increased sodium 
consumption[39]. 
Salt-inducible kinase 1 activity has been demonstrated as necessary to prevent the 
development of high blood pressure under chronic high salt intake[39]. However, it is possible that 
SIK1 activity in other tissues besides VSMCs can also be relevant for blood pressure regulation 
through other unknown salt-inducible mechanisms[39]. For instance, growing evidence has been 
progressively proposing the gastrointestinal tract as a key element in the regulation of 
cardiometabolic homeostasis – besides the association of anatomical structure, gut microbiota, 
gut autonomic nerve activity and gut hormone secretion with blood pressure regulation, it is 
unanimously accepted that excessive intestinal absorption of sodium contributes to the 
 development of hypertension[39, 40]. Regarding these aspects, we hypothesize that SIK1 activity 
present in other tissues such as the gastrointestinal tract may represent an alternative pathway 
for blood pressure regulation under chronic high salt intake and a potentially promising target for 
the comprehension and management of hypertension. 
 
The present work – in which the role of salt-inducible kinase 1 on sodium-sensible 
hypertension development was further explored – has two different sections. 
In Part I, we characterized the effects of SIK1 ablation on blood pressure, focusing on renal 
and sympathetic nervous system mechanisms of salt-induced hypertension. 
In Part II, we took a first step in investigating the interplay between Na+-K+-ATPase and 
basolateral KATP channels in intestinal cells, focusing on the characterization of intestinal ion 
transport mechanisms that are potentially subject to SIK1 regulation. 
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Abstract
Loss of salt-inducible kinase 1 (SIK1) triggers an increase in blood pressure (BP) upon a chronic high-salt intake in mice.
Here, we further addressed the possible early mechanisms that may relate to the observed rise in BP in mice lacking SIK1.
SIK1 knockout (sik1 −/−) and wild-type (sik1 +/+) littermate mice were challenged with either a high-salt (8% NaCl) or
control (0.3% NaCl) diet for 7 days. Systolic BP was significantly increased in sik1 −/− mice after 7 days of high-salt diet as
compared with sik1 +/+ mice and to sik1 −/− counterparts on a control diet. The renin–angiotensin–aldosterone system and the
sympathetic nervous system were assayed to investigate possible causes for the increase in BP in sik1 −/− mice fed a 7-day
high-salt diet. Although no differences in serum renin and angiotensin II levels were observed, a reduction in aldosterone
serum levels was observed in mice fed a high-salt diet. Urinary L-DOPA and noradrenaline levels were significantly
increased in sik1 −/− mice fed a high-salt diet as compared with sik1 −/− mice on a control diet. Similarly, the activity of
dopamine β-hydroxylase (DβH), the enzyme that converts dopamine to noradrenaline, was significantly increased in the
adrenal glands of sik1 −/− mice on a high-salt intake compared with sik1 +/+ and sik1 −/− mice on a control diet. Treatment
with etamicastat (50 mg/kg/day), a peripheral reversible DβH inhibitor, administered prior to high-salt diet, completely
prevented the systolic BP increase in sik1 −/− mice. In conclusion, SIK1 activity is necessary to prevent the development of
salt-induced high blood pressure and associated SNS overactivity.
Keywords SIK1 ● High-salt intake ● Sympathetic nervous system ● Dopamine β-hydroxylase ● Hypertension
Introduction
Salt-inducible kinase 1 (SIK1) is a sucrose non-fermenting-
like kinase isoform that belongs to the AMP-activated protein
kinase (AMPK) family of serine/threonine kinases [1]. SIK1
is part of a cell sodium-sensing network that regulates active
sodium transport through a calcium-dependent process [2].
SIK1 activity is increased by high-salt intake and is impli-
cated in regulation of the plasma membrane Na+, K+-ATPase
(NKA) activity [3]. SIK1 regulates active sodium transport in
the renal and lung epithelia by increasing NKA activity and
mediates gene expression activation in cardiac myocytes
upon increase in intracellular sodium [2, 4, 5]. Variations in
intracellular sodium concentrations upon increases in cell
sodium permeability triggers the activation of plasma mem-
brane NKA activity in order to maintain cellular homo-
eostasis. Consequently, the lack of SIK1 is associated with
reduction in NKA activity and protein [6, 7].
SIK1 is also localised in human vascular smooth muscle
cells (VSMCs) and endothelial cells, and its activity appears
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to be of potential relevance for VSMCs function and blood
pressure regulation [8]. A nonsynonymous single-
nucleotide polymorphism in the hSIK1 gene exon 3
results in the amino acid change (15)Gly→ Ser in the SIK1
protein, which is associated with lower blood pressure and
with a decrease in left ventricular mass [8]. Moreover, SIK1
is also present in the brain, and it has been proposed that
dysregulation of the SIK1–NKA network in neurons con-
tributes to salt-induced hypertension through angiotensin-
mediated sympathetic hyperactivity by increasing intracel-
lular [Ca2+] [9, 10]. Recently, we demonstrated that the lack
of SIK1 contributes to the vascular remodelling processes,
e.g., dysregulated collagen synthesis and increased con-
tractile phenotype of VSMCs, leading to increased vascular
stiffness and consequently to higher blood pressure upon a
chronic high-salt diet in mice [11].
The sympathetic nervous system plays a role in the
regulation of cardiovascular function, and increased acti-
vation of the sympathetic nervous system has been claimed
to be involved in the the pathophysiology of hypertension
[12, 13], despite to date augmented sympathetic activity
having been demonstrated only in a minority of hyperten-
sive patients [14]. The increase in sympathetic activity has
been demonstrated to be organ specific, in particular to the
heart and kidneys, rather than being generalised, and is
associated to increase mortality [14]. Evidence has also
been obtained that sympathetic activation participates in the
development of hypertension-related target organ damage,
such as left ventricular diastolic dysfunction, left ventricular
hypertrophy and arterial remodelling and hypertrophy [15].
Sympathetic cardiovascular influences may favour the
hypertensive phenotype, by concurring with other hemo-
dynamic and non-hemodynamic factors at the development
of target organ damage [16, 17].
Dopamine β-hydroxylase (DβH) is the enzyme that cat-
alyses the hydroxylation of dopamine (DA) to noradrena-
line (NA) in the sympathetic nervous system. DβH
inhibition causes sympathetic slowdown by reducing NA
levels, and additionally leads to increased DA availability.
The increase in DA levels can further promote renal vaso-
dilation, natriuresis and diuresis [18, 19]. Etamicastat
(development code BIA 5-453) is a peripherally selective
and reversible inhibitor of DβH, currently under clinical
development for the treatment of hypertension and heart
failure [20–22]. Etamicastat displays a mixed (non-compe-
titive) type DβH inhibition with respect to DA with a
low nM Ki value. In contrast to what its found in the per-
ipheral tissues, etamicastat does not affect DA or NA tissue
levels in the brain [22]. Etamicastat, when administered to
spontaneously hypertensive rats (SHR), produced a dose-
dependent reduction in both systolic and diastolic
blood pressures [23]. Additionally, chronic administration
of etamicastat in drinking water, significantly reduced
both blood pressure and urinary excretion of NA in
SHR [20].
In the present study, we investigated the effect of SIK1
ablation on blood pressure after a 7-day high-salt diet in
mice, focusing on the renal and sympathetic mechanisms of
salt-induced hypertension.
Methods
Animal care and general procedures
The sik1 −/− mice were purchased from Taconic Biosciences
Inc. (Model #TF1350, Rensselaer, NY, USA) and pre-
viously described [4]. Colony was maintained on a het-
erozygous breeding scheme. Homozygous male SIK1
knockout (sik1 −/−) and wild-type (sik1 +/+) littermate mice
were used in this study. Animals were housed in macrolon
cages (Tecniplast, Varese, Italy) with free access to food
(#2014 Teklad Global Rodent Diets®, Envigo, Barcelona,
Spain) and tap water under controlled environmental con-
ditions in a colony room (12 h light/dark cycle, room tem-
perature: 22 ± 2 °C and relative humidity: 50 ± 20%) until
the beginning of the experiments. Eight-week-old male
sik1 −/− and sik1 +/+ littermate control mice were challenged
either a high-salt (8% NaCl, #D02011103) or control (0.3%
NaCl, #D02112603) AIN-76A rodent diet (Research Diets
Inc., New Brunswick, NJ, USA) for 7 days. Animal pro-
cedures conformed to the guidelines from Directive 2010/
63/EU of the European Parliament on the protection of
animals used for scientific purposes and the Portuguese law
on animal welfare (Decreto-Lei 113/2013).
Blood pressure measurement
Implantable telemetry was used for blood pressure, heart
rate and home-cage activity assessment. Mice were anaes-
thetised by intraperitoneal injection (10 ml/kg of body
weight) of ketamine (150 mg/kg of body weight), medeto-
midine (1 mg/kg of body weight) and butorphanol (1 mg/kg
of body weight) in the normal saline solution. Mice were
instrumented with radio-telemeters (#TA11PA-C10, Data
Sciences International, St Paul, MN, USA), as described
elsewhere [11, 24]. Briefly, telemetry transmitter was
inserted into the carotid artery after cranial permanent
ligature and temporary caudal occlusion. Catheter tip was
positioned and secured in the aortic arch. Post-operative
care: wound closure was covered with 2% lidocaine cream
and carprofen (5 mg/kg/day s.c.) was administered for
3 days, twice daily. Animals recovered individually before
experiments. After recovery, telemetry probes were mag-
netically turned-on and blood pressure, heart rate and home-
cage locomotor activity were monitored. Raw data were
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recorded for 40 s every 10 min for 48 h using Dataquest A.
R.T. Acquisition and Analysis system 4.0 (Data Sciences
International).
Renal function
After telemetry recording, mice were individually placed in
mouse metabolic cages (Tecniplast) for a 24-h urine col-
lection. The volume of water intake and urinary excretion
was noted. The urine samples were collected and stored at
−80 °C until assayed.
Biochemical parameters
After completion of the protocol, mice were weighed and
anaesthetised (60mg/kg of body weight, i.p.) with sodium
pentobarbital (Merck, Darmstadt, Germany) and killed by
abdominal vena cava exsanguination. Blood samples (≈600 µl)
were collected (Multivette® 600 Z, Sarstedt, Nümbrecht, Ger-
many) and centrifuged (4 °C, 10,000g, 5 min). Aliquoted
serum samples were immediately snap-frozen in liquid
nitrogen and stored at −80 °C until analyses. The heart,
abdominal aorta and kidneys were exposed, rapidly excised
and blotted dry; atria, ventricles and kidneys weight was
recorded. Kidney mass weight-to-body weight ratio was used
as an index of renal hypertrophy. All biochemical assays were
performed by Cobas Mira Plus analyzer (ABX Diagnostics for
Cobas Mira, Basel, Switzerland). Serum aldosterone levels
were measured using a commercially available ACTIVE®
Aldosterone 125I radioimmunoassay (RIA) kit (Beckman
Coulter, Inc., Brea, CA, USA, ref. DSL8600) according to the
manufacturer's instruction and quantified on a gamma counter.
Serum renin (Merck, Mouse Ren1/Renin-1 ELISA Kit, ref.
RAB0565) and angiotensin II (Merck, Angiotensin II EIA Kit
ref. RAB0010) levels were quantified by commercially
available standard immunoassay kits following the manufac-
turer's instructions.
Assay of catecholamines
NA and DA levels were quantified in the kidney cortex,
atria, ventricles and abdominal aorta. NA, DA, L-3,4-
dihydroxyphenylalanine (L-DOPA) and 3,4-dihydrox-
yphenylacetic acid (DOPAC) levels were quantified in 24-h
urine samples. All samples were analysed using a high-
performance liquid chromatography system (Gilson Inc.,
Middleton, WI, USA) with electrochemical detection
(HPLC-ED) as previously described [25].
Assay of DβH activity
DβH activity was determined in adrenal glands homo-
genates. In brief, adrenal glands were removed, placed in
200μL of 50 mM Tris (Merck), pH 7.4 and stored at −80 °C
until analysis. Determination of DβH activity was per-
formed according to the method of Nagatsu and Udenfriend
[26]. DβH activity was assessed by measuring the quantity
of octopamine formed (expressed in ng/mg of protein/min)
as described before [21].
mRNA expression
Kidney tissue samples were directly incubated with RNA-
later (Thermo Fisher Scientific Inc., Waltham, MA, USA).
RNA was extracted with RNeasy tissue kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s instruc-
tions, with an additional step for genomic DNA removal.
Quantification was performed on a 2100 Bioanalyzer
(Agilent Technologies Inc., Santa Clara, CA, USA) using
RNA 6000 Nano LabChip Kits (Agilent Technologies). All
samples had a RIN value ≥ 7.5 and concentration of 1.3–2.8
µg/µl. In total, 0.5 µg of RNA were reverse-transcribed
using high capacity cDNA reserve transcription kit (Applied
Biosystems Inc., Foster City, CA, USA), per the manu-
facturer’s instructions. For gene expression assay, a Taq-
Man array 96-well plate fast plate custom format 16 plus
candidate endogenous control genes (PN4413262) was
used. This array included three mouse endogenous genes
(Gapdh, Hprt1 and Gusb) and 12 mouse inventoried genes
(related to renal regulation of Na+ balance). In total, 0.5 µg
of cDNA per sample were amplified using the 2X TaqMan
Fast Universal PCR Master Mix, no AmpErase UNG
(Applied Biosystems), per the manufacturer’s instructions.
qPCR was performed on a StepOnePlus Real-Time PCR
System (Applied Biosystems). Raw data were analysed with
DataAssist software v.3.01 (Applied Biosystems) using the
Δ-ΔCt method (relative quantification). The relative amount
of the mRNA of interest was normalized against to Hprt1
mRNAs using the comparative Ct method.
Treatment with etamicastat
Etamicastat was synthesized in the Laboratory of Chemistry
of BIAL-Portela & Cª, S.A. [Coronado (S. Romão e S.
Mamede)] with a purity grade > 96% [27]. Mice were
administered 50 mg/kg/day etamicastat in drinking water.
Etamicastat treatment started 7 days before high-salt intake
and lasted until the end of the experiment. The daily dose of
etamicastat attained for the entire experimental period was
55.6 ± 1.6 mg/kg of body weight.
Statistical analysis
The data are presented as the mean ± SEM. Data analyses
were performed using Prism 6 (GraphPad Software, San
Diego, CA, USA). The data were analysed by one-way
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analysis of variance (ANOVA) followed by Fisher’s least
significant difference (LSD) test or unpaired t test, as
appropriate. A value of P < 0.05 was considered statistically
significant.
Results
Loss of SIK1 increases blood pressure upon an acute
high-salt intake in mice
Blood pressure and heart rate recordings were performed on
telemetered sik1 −/− and sik1 +/+ littermate mice challenged
to either a high-salt or control diet for 7 days. No differ-
ences in blood pressure were observed between sik1 −/− and
sik1 +/+ mice on a control diet (Fig. 1 and Supplementary
Fig. S1). However, upon a 7-day high-salt intake, systolic
blood pressure was significantly elevated in sik1 −/− mice
(137 ± 7 mm Hg) as compared with sik1 +/+ mice (121 ± 2
mm Hg, P= 0.0054) and to sik1 −/− mice on a control diet
(125 ± 7 mm Hg, P= 0.0218). Likewise, mean arterial
pressure was significantly elevated in sik1 −/− mice (122 ± 9
mm Hg) compared with sik1 +/+ mice (106 ± 3 mm Hg, P=
0.0265) on a high-salt diet, whereas diastolic blood pressure
was similar in both groups (Fig. 1 and Supplementary
Fig. S1). No differences in heart rate and home-cage activity
were observed between groups (Fig. 1 and Supplementary
Fig. S1).
Renal function and the renin–angiotensin system in
the sik1−/− mice
Body weight, kidney hypertrophy and urinalysis in sik1 −/−
and sik1 +/+ mice on a control and high-salt diet are sum-
marized in Table 1. SIK1 ablation had no effect on body
weight. Conversely, on a high-salt diet, sik1 +/+ mice were
slightly, but significantly, heavier than their counterparts on
a control diet. Kidney weight-to-body weight ratio in sik1 −/−
mice was significantly higher, under both diet protocols as
well as in wild-type mice fed a high-salt diet. Water intake
and urinary volume output were similar between both
genotypes, under both diet protocols. Upon high-salt intake,
the water consumption increased by 2.8- and 2.1-fold in
both genotypes, sik1 +/+ and sik1 −/− mice, respectively, and
Fig. 1 Blood pressure, heart rate
and home-cage activity in
telemetered salt-inducible kinase
1 (SIK1) knockout (sik1 −/−) and
wild-type (sik1 +/+) littermate
mice challenged either a high-
salt (8% NaCl) or control (0.3%
NaCl) diet for 7 days.
(a) Systolic blood pressure
(SBP), (b) diastolic blood
pressure (DBP), (c) mean
arterial pressure (MAP), (d )
heart rate (HR) and (e) home-
cage activity. Mean ± SEM; n=
6–9 per group; values were
determined to be significantly
different from sik1 +/+ mice (*P
< 0.05) or control diet-fed
counterparts (#P < 0.05) group
by one-way analysis of variance
followed by Fisher’s least
significant difference (LSD) test
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this was accompanied by an increase in urinary volume
output. Under control diet feeding, urinary creatinine levels
were not different between sik1 +/+ (0.62 ± 0.03 µmol/mg)
and sik1 −/− mice (0.48 ± 0.04 µmol/mg), moreover high-salt
intake had no effect on urinary creatinine (0.62 ± 0.04 and
0.57 ± 0.05 µmol/mg, respectively). Likewise, no differ-
ences between genotypes were observed in the daily urinary
excretion of sodium, potassium or chloride on a control diet.
A high-salt intake significantly increased urinary sodium
and chloride output in both genotypes. Conversely, the
urinary potassium levels were 1.9-fold higher exclusively in
sik1 −/− mice after a high-salt diet. Likewise, sodium and
potassium excretion were significantly increased in sik1 −/−
animals, but not in wild-type control mice, under a high-salt
intake.
Serum renin, angiotensin II and aldosterone levels were
similar between sik1 −/− and wild-type mice, under both salt
regimens. Serum aldosterone levels significantly decreased
in the high-salt diet protocol, in a similar extent, in both
genotypes (Table 2).
To further assess the causes of the increased blood
pressure in sik1 −/− mice upon a high-salt intake, the
expression of genes related to renal regulation of sodium,
was evaluated in kidney tissue samples. There was no
difference in gene expression levels between sik1 −/− and
sik1 +/+ mice fed a control or high-salt diet (Supplementary
Table S1).
Sympathetic activity upon acute high-salt intake in
the sik1−/− mice
Catecholamine levels were assessed in urine and in several
peripheral organs. Regarding tissue levels of catechola-
mines, no significant changes were detected in the kidney,
atria, ventricles and aorta of sik1 −/− and sik1 +/+ mice fed
either control or high-salt diet for 7 days (Table 3). Twenty-
four-hour urine was collected in metabolic cages, after
control or high-salt diet feeding in sik1 +/+ and sik1 −/− mice.
As shown in Fig. 2a, NA excretion was 58% decreased in
urine samples from the sik1 −/− mice on a control diet, but
increased 2.9-fold after high-salt intake. As depicted in
Fig. 2, an increase of DA metabolites, DOPAC and its
precursor L-DOPA, were also reported during high-salt
intake, but no significant differences were detected in DA
levels.
DβH activity was evaluated in adrenal gland homo-
genates. Under a control diet, DβH activity was similar in
both genotypes. Upon challenge with a high-salt diet, DβH
activity increased in both sik1 −/− and wild-type mice, but to
a greater extent in the sik1 −/− mice (Fig. 3).
DβH activity and catecholamine levels were measured in
knockout mice fed a high-salt diet after pre-treatment with
etamicastat, a reversible inhibitor of peripheral DβH. In the
sik1 −/− mice on a high-salt diet regimen, etamicastat led to a
59% decreased in the adrenal DβH activity (Fig. 4).
Regarding catecholamine levels in urine, kidney, ventricles,
atria and aorta, etamicastat reduced NA in urine and in all
tissues analysed in sik1 −/− mice after high-salt intake (Fig. 5
and Table 4). Etamicastat had no effect on urinary L-DOPA
levels (Fig. 5). On the other hand, DA and DOPAC levels
were increased in both urine and tissues (Fig. 5 and Table 4).
Etamicastat and blood pressure in the sik1−/− mice
Blood pressure and heart rate recordings were assessed on
telemetry-implanted sik1 −/− mice after 14 days of treatment
Table 1 Renal function after
7 days of 0.3 or 8% NaCl intake
in sik1 +/+ and sik1 −/− mice
0.3% NaCl diet 8% NaCl diet
sik1 +/+ sik1 −/− sik1 +/+ sik1 −/−
Body weight (g) 25.7 ± 0.6 25.8 ± 1.1 29.2 ± 0.9# 28.2 ± 0.5
Kidney-to-body weight ratio (mg/g) 11.3 ± 0.2 13.0 ± 0.2* 12.6 ± 0.2# 13.9 ± 0.2*
Water intake (ml/24 h) 2.5 ± 0.2 3.3 ± 0.5 6.9 ± 0.6# 6.8 ± 0.7#
Urinary output (ml/24 h) 1.6 ± 0.2 1.0 ± 0.2 3.5 ± 0.7# 4.3 ± 0.6#
Urine creatinine (mg/24 h) 0.62 ± 0.03 0.48 ± 0.04 0.62 ± 0.04 0.57 ± 0.05
Urine sodium/creatinine ratio (µmol/mg) 119 ± 8 107 ± 11 2075 ± 450# 3041 ± 251* #
Urine potassium/creatinine ratio (µmol/mg) 220 ± 10 183 ± 13 251 ± 27 341 ± 15* #
Urine chloride/creatinine ratio (µmol/mg) 403 ± 36 405 ± 43 1719 ± 340# 2268 ± 157#
Mean ± SEM, n= 5–6 per group. *P < 0.05 as compared with sik1 +/+ mice; #P < 0.05 as compared with
0.3% NaCl feeding counterparts
Table 2 Serum renin, angiotensin II and aldosterone levels after
1 week of 0.3 or 8% NaCl intake in sik1 +/+ and sik1 −/− mice
0.3% NaCl diet 8% NaCl diet
sik1 +/+ sik1 −/− sik1 +/+ sik1 −/−
Renin 465 ± 22 463 ± 18 462 ± 33 463 ± 32
Angiotensin II 33 ± 7 46 ± 10 44 ± 7 39 ± 9
Aldosterone 267 ± 67 197 ± 30 83 ± 9# 78 ± 6#
All= pg/ml. Mean ± SEM, n= 3–6 per group. #P < 0.05 as compared
with 0.3% NaCl feeding counterparts
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with etamicastat, in which in the last 7 days, animals were
fed a high-salt diet. As depicted in Fig. 6, etamicastat
treatment prevented the increase in systolic blood pressure
caused by a 7-day high-salt diet feeding in sik1 −/− mice. A
small, but significant, decrease in heart rate was also
observed after etamicastat treatment (Fig. 6 and Supple-
mentary Fig. S2).
Discussion
Here, we proposed to study the role of SIK1 on blood
pressure rise after a 7-day period of high-salt intake, namely
by evaluating the role of renal and sympathetic mechan-
isms. Our results suggest that SIK1 has a direct effect on
blood pressure regulation via the sympathetic nervous sys-
tem. These results confirm and extend our previous obser-
vations that vascular SIK1 activation might represent a
mechanism involved in the prevention of high blood pres-
sure and highlights the relevance of SIK1 in blood pressure
regulation in vivo [6, 11].
SIK1 modulates NKA activity and contributes to the
reabsorption of sodium in the kidney proximal tubules. This
is in agreement with the increased natriuresis observed after
7 days on high-salt diet, where sik1 −/− mice excreted 1.5-
fold more sodium than sik1 +/+ mice on the same diet regi-
men, as creatinine excretion rates were similar. This differ-
ence in renal electrolyte handling should have led to a lower
blood pressure in sik1 −/− mice as compared with sik1 +/+
mice feed a high-salt diet. Nevertheless, the contribution of
Table 3 Tissue catecholamine
levels after 1 week of 0.3 or 8%
NaCl intake in sik1 +/+ and
sik1 −/− mice
0.3% NaCl diet 8% NaCl diet
sik1 +/+ sik1 −/− sik1 +/+ sik1 −/−
Kidney
Noradrenaline 2291 ± 195 2653 ± 222 2603 ± 137 2878 ± 232
Dopamine 423 ± 43 381 ± 42 331 ± 11 351 ± 58
Ventricles
Noradrenaline 2962 ± 183 2559 ± 161 2765 ± 163 2629 ± 240
Dopamine 217 ± 18 169 ± 8 175 ± 7 153 ± 15
Atria
Noradrenaline 6590 ± 673 7017 ± 1026 7047 ± 625 7474 ± 728
Dopamine 833 ± 121 754 ± 73 746 ± 38 836 ± 102
Aorta
Noradrenaline 6799 ± 992 8128 ± 971 8215 ± 490 9337 ± 1933
Dopamine 681 ± 62 661 ± 55 799 ± 73 727 ± 112
All= pmol/g tissue. Mean ± SEM, n= 5 per group
Fig. 2 Urinary L-DOPA,
catecholamines and metabolites
in salt-inducible kinase 1 (SIK1)
knockout (sik1 −/−) and wild-
type (sik1 +/+) littermate mice
challenged either a high-salt (8%
NaCl) or control (0.3% NaCl)
diet. a Noradrenaline,
(b) L-DOPA, (c) dopamine and
(d ) 3,4-dihydroxyphenylacetic
acid (DOPAC). Mean ± SEM; n
= 6 per group; values were
determined to be significantly
different from sik1 +/+ mice (*P
< 0.05) or from control diet-fed
counterparts (#P < 0.05) group
by one-way analysis of variance
followed by Fisher’s least
significant difference (LSD) test
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SIK1 in controlling the vascular tone [6, 8, 11] seems to
surpass the contribution of renal SIK1 which could also be
compensated by other SIK isoforms mechanisms, leading to
a higher blood pressure in sik1 −/− than in sik1 +/+ mice,
under a high-salt diet [11].
In an attempt to uncover the mechanisms that may be
responsible for the increase in blood pressure upon high
sodium diet in the sik1 −/− mice, the renin–angiotensin
system was evaluated as a potential trigger for the rise in
blood pressure. On a high-salt regimen, serum aldosterone
levels were significantly lower in both sik1 +/+ and sik1 −/−
mice compared with mice on a control diet, indicating a
negative feedback loop of the renin–angiotensin system.
Despite the significant increase in sodium excretion and a
Fig. 3 Dopamine β-hydroxylase (DβH) activity in adrenal glands
of salt-inducible kinase 1 (SIK1) knockout (sik1 −/−) and wild-type
(sik1 +/+) littermate mice challenged either a high-salt (8% NaCl) or
control (0.3% NaCl) diet. Mean ± SEM; n= 5 per group; values were
determined to be significantly different from sik1 +/+ mice (*P < 0.05)
or from control diet-fed counterparts (#P < 0.05) group by one-way
analysis of variance followed by Fisher’s least significant difference
(LSD) test
Fig. 4 Effect of etamicastat (ETA) treatment on dopamine β-
hydroxylase (DβH) activity in adrenal glands of salt-inducible kinase
1 (SIK1) knockout (sik1 −/−) mice challenged with a high-salt (8%
NaCl) diet. Mean ± SEM; n= 7 to 8 per group; values were deter-
mined to be significantly different from high-salt diet group (*P <
0.05) by unpaired t test
Fig. 5 Effect of etamicastat
(ETA) treatment on urinary
L-DOPA, catecholamines and
metabolites in salt-inducible
kinase 1 (SIK1) knockout
(sik1 −/−) mice challenged with
a high-salt (8% NaCl) diet.
a noradrenaline, (b) L-DOPA,
(c) dopamine and (d )
3,4-dihydroxyphenylacetic acid
(DOPAC). Mean ± SEM; n= 7–
8 per group; values were
determined to be significantly
different from 8% NaCl diet
group (*P < 0.05) by unpaired t
test
Table 4 Tissue catecholamines levels after one week of 50 mg/kg/day
etamicastat (ETA) treatment in sik1 −/− mice on an 8% NaCl intake
8% NaCl diet ETA+ 8% NaCl diet
Kidney
Noradrenaline 2437 ± 169 1136 ± 98*
Dopamine 408 ± 29 1169 ± 72*
Ventricles
Noradrenaline 3723 ± 224 1736 ± 224*
Dopamine 298 ± 30 1672 ± 178*
Atria
Noradrenaline 8913 ± 987 2484 ± 187*
Dopamine 898 ± 126 2500 ± 98*
Aorta
Noradrenaline 7315 ± 1431 3209 ± 444*
Dopamine 968 ± 186 5707 ± 340*
All= pmol/g tissue. Mean ± SEM, n= 7 per group. *P < 0.05 as
compared with 8% NaCl diet group
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decrease in serum aldosterone levels, no decrease in circu-
lating renin was observed. The effect of high-salt diet on
renin activity is unknown as only circulating renin mass was
addressed. A possible explanation for this conundrum is that
blood samples were obtained from pentobarbital-
anaesthetised mice. Meneton et al. have shown that
plasma renin concentration is increased by pentobarbital
anaesthesia [28]. Nonetheless, no differences between
genotype in serum renin levels were found on both diet
protocols, suggesting that the loss of SIK1, under a high-salt
intake, leads to an altered electrolyte excretion and to hea-
vier kidneys without the involvement of the renin–angio-
tensin system pathway. This is in line with the finding that
the C57BL/6 mouse strain appear to be resistant to
hypertension-induced renal injury [29] and renal injury
caused by angiotensin II infusion, protein load or renal
ablation [30–32]. Moreover, abnormalities in the renin–
angiotensin system do not seem to be implicated in the salt
sensitivity of C57BL/6 mice [33].
To evaluate whether the sympathetic nervous system
contributes to the elevation of blood pressure observed in
the sik1 −/− mice during a high-salt diet, catecholamine
levels in urine and in several peripheral tissues were mea-
sured. Urinary NA, DA and L-DOPA levels were reduced
more than 50% in the sik1 −/− mice compared with the wild-
type counterparts. SIK1 is a well-studied cell sodium-
sensing mechanism that controls intracellular sodium con-
centration by regulating NKA activity. Therefore, a possible
explanation for the reduced urinary L-DOPA levels in the
SIK1−/− mice could be a reduction in the intracellular
transport of L-DOPA into kidney cells as a consequence of
a decreased NKA activity. The impaired transport of L-
DOPA would also account for the reduced levels of DA,
since uptake of L-DOPA is the rate-limiting step for DA
synthesis in the kidney. However, basal NKA activity, at
normal intracellular sodium, remains unaffected under
conditions when SIK1 activity is suppressed, which indi-
cates that in the absence of SIK1, reduced L-DOPA trans-
port does not account for the changes in L-DOPA and DA
[6]. The reduction in L-DOPA levels due to a reduction in
catecholamine synthesis can better account for this reduc-
tion, as well as in overall sympathetic NA.
Plasmatic L-DOPA is derived substantially, albeit not
exclusively, from catecholamine biosynthesis from sympa-
thetic nerves endings [34]. Tyrosine hydroxylase (TH) is the
enzyme responsible for the conversion of tyrosine to L-
DOPA and is considered the rate-limiting step for cate-
cholamine synthesis. TH is highly regulated at the post-
Fig. 6 Effect of 50 mg/kg/day
etamicastat (ETA) treatment on
blood pressure, heart rate and
home-cage activity in
telemetered salt-inducible kinase
1 (SIK1) knockout (sik1 −/−)
mice challenged with a high-salt
(8% NaCl) diet. ETA treatment
for 14 days, in which in the last
7 days, animals were fed a high-
salt diet. a Systolic blood
pressure (SBP), (b) diastolic
blood pressure (DBP), (c) mean
arterial pressure (MAP),
(d ) heart rate (HR) and
(e) home-cage activity. Mean ±
SEM; n= 5 to 6 per group;
values were determined to be
significantly different from high-
salt diet group (*P < 0.05) by
unpaired t-test
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translational level by phosphorylation at several serine
residues [35]. Phosphorylation of TH is associated with an
increased enzymatic activity and plays a key role in the
regulation of the sympathetic system. SIK1 belongs to the
family of AMPK and has been shown to phosphorylate TH,
thereby potentially regulating the activity of this enzyme
[36]. Absence of SIK1 could result in downregulation of
TH phosphorylation leading to a reduction in L-DOPA
synthesis and release from the sympathetic terminals, that
could account for the lower levels of the catecholamine
precursor in urine. Reduction of catecholamine synthesis in
sympathetic terminals would also account for the fact that
NA levels in urine was reduced in sik1 −/− as compared with
sik1 +/+ mice. On the other hand, in this study no significant
changes in NA levels in cardiovascular and kidney tissue
or in plasma NA levels were observed as previously
described [11].
NA levels in sympathetic terminals are constantly fluc-
tuating due to the highly dynamic regulation of its synth-
esis, release, re-uptake and metabolism [37]. Moreover, the
majority of NA in sympathetic terminals is stored in vesi-
cles, and only a small percentage (about 10%) being
syphoned to the circulation. It was therefore not surprising
that, in the sik1 −/− mice, the tissue levels of NA were
unaltered, which is in line what we previously observed in
the plasma [11]. On contrary, levels in the urine provide a
good indication of overall changes that occur in sympathetic
drive by taking into account fluctuations that occur over a
24-h period.
Interestingly, DβH activity in adrenals was found not to
be altered, and even with a small tendency to be increased.
Unlike TH, DβH is not subjected to tight regulation but
nevertheless plays a crucial role in NA synthesis, as it is
responsible for the conversion of DA to NA [38].
In control diet groups, sik1 −/− mice had lower urinary
NA than wild-type mice, whereas there was no difference in
systolic blood pressure between these two groups. In high-
salt diet groups, on the other hand, sik1 −/− mice displayed a
higher systolic blood pressure than sik1 +/+ mice while their
urinary NA is similar. The increase in blood pressure
observed in the sik1 −/− mice after high-salt diet, is likely to
be caused by a burst of sympathetic activity as revealed by
the increase in urinary excretion of NA and by the increase
in adrenal DβH activity. Upon high-salt intake, there was
a significant increase in L-DOPA and NA levels in the
sik1 −/− mice, but not in wild-type littermates. As stated
above, fluctuations in L-DOPA levels are likely to be due to
an increase in synthesis by changes in the enzyme respon-
sible for catecholamine synthesis, TH. In fact, increased
sympathetic TH activity and increased NA levels have been
demonstrated in the kidney of a rodent model of hyper-
tension [39]. The inability to inhibit noradrenargic activity
may lead to prolonged peripheral vasoconstriction,
ultimately leading to hypertension. Moreover, a significant
increase in DβH activity was observed in both, sik1 −/− and
sik1 +/+ mice, but the overall activity was higher in the
sik1 −/− mice. Therefore, in the sik1 −/− mice the high-salt
intake triggers a surge in sympathetic activity, leading to an
increase in NA synthesis and release. In light of this, it
could be argued that SIK1 has evolved to act as the
buffering system for sympathetic nervous system activity.
The observed overdrive of the sympathetic nervous system,
namely the noradrenergic and adrenergic tone in the
SIK1-null mice may partially explain the increase in blood
pressure triggered by a high-salt intake, which is also
consistent with the over-activation of DβH. These results
reveal a determinant role of SIK1 in the sympathetic ner-
vous system upon an acute high-salt intake.
Etamicastat is a potent and reversible inhibitor of DβH
that prevents the conversion of DA to NA in peripheral
sympathetically innervated tissues, thereby decreasing the
sympathetic nervous system drive [17]. In contrast to what
is found in the peripheral tissues, etamicastat does not affect
DA and NA levels in the brain [22]. Etamicastat was tested
in animal models predictive of efficacy of drugs in cardio-
vascular disorders. In SHR, etamicastat reduced systolic and
diastolic blood pressure alone or in combination with anti-
hypertensive drugs [20, 23]. In this study, administration
of etamicastat prevented the rise in blood pressure in the
sik1 −/− mice fed with a high-salt intake. As expected,
treatment with etamicastat produced a significant decrease
in NA levels and a significant increase in DA levels in
cardiovascular tissues, which is associated with the inhibi-
tion of DβH activity. In the kidney, treatment with etami-
castat also produced the same effect as seen in the
cardiovascular tissue, a decrease in NA levels and an
increase in DA levels. This effect is most likely due to the
inhibition of DβH in sympathetic nerve terminals since
kidney cells are not endowed with DβH and synthesize
dopamine from circulatory L-DOPA. Overall, the reduction
in sympathetic activation was accompanied by a significant
decrease in NA levels and increase in DA levels in the
urine. The latter could be attributed in part to the inhibition
of DβH, but since DA found in urine derives mostly from
newly synthesized DA in the kidney, it is more likely that
the increase in DA urinary levels is due to increased renal
synthesis [40]. The increase in DA and the decrease in NA
leads to an increase in the DA-to-NA ratio, that can be taken
as a natriuretic index. In a situation when sodium excretion
needs to be enhanced, the DA-to-NA ratio should be
increased, as the two hormones have opposite actions on
sodium reabsorption and vascular resistance [41]. The
inability of the kidney to respond to the increased dopa-
minergic system activity, through increased dopamine
synthesis, could further underscore the idea that an
increased activity of the noradrenergic system may be
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responsible for the imbalance in sodium, ultimately leading
to manifest hypertension [42, 43].
Taken together, the data presented here support the view
that SIK1, an intracellular sodium-sensing mechanism, by
regulating the activity of the sympathetic nervous system
affects blood pressure. Efforts aimed at decreasing sympa-
thetic drive by targeting SIK1, could prove to be an inter-
esting strategy in the management, treatment/prevention of
sodium sensitive hypertension that results from an imbal-
ance of renal sodium concentration.
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 Introduction 
Although numerous general mechanisms involved in sodium transcellular transport and 
homeostasis have been recognized in renal proximal tubule cells, the gastrointestinal tract and the 
kidney share substantial similarities in epithelial ion transport, as basolateral Na+-K+-ATPase 
represents the driving force for the movement of numerous substrates across cell membrane, 
being subject to parallel regulatory mechanisms[41-43]. 
During transcellular salt uptake, sodium-absorbing epithelia are recognized for their 
ability to match the rates of passive sodium entry across the apical membrane and active sodium 
extrusion across the basolateral membrane in order to maintain intracellular Na+ concentrations 
constant[44]. Sodium is actively extruded from the cell by Na+-K+-ATPase at the expense of 
potassium entrance[45]. Therefore, changes in apical Na+ entry proceed in concern with changes 
in Na+-K+-ATPase activity and thus affect K+ uptake across the basolateral membrane[46]. Since K+ 
recycling is necessary for continued sodium pump turnover, changes in NKA activity result in 
reciprocal adjustments in basolateral K+ conductance, maintaining intracellular K+ concentrations 
constant[46, 47]. This functional coupling between Na+-K+-ATPase activity and basolateral K+ 
channel activity (pump-leak) is mediated by ATP-sensitive K+ (KATP) channels[45]. 
KATP channels are inwardly rectifying ATP-modulated channels present in the basolateral 
membrane composed of four pore-forming Kir6.x subunits and four auxiliary SURx proteins[48]. 
These channels show an essentially voltage-independent activity that relies on intracellular 
nucleotides, as its opening is inhibited by adenosine triphosphate (ATP) and activated by adenosine 
diphosphate (ADP): stimulation of Na+-K+-ATPase activity results in decreased intracellular ATP 
levels, which in turn open the KATP channels and increase basolateral K+ conductance[45, 47-49]. 
Opening of KATP channel causes membrane hyperpolarization, facilitating the K+ recycling required 
for continued Na+-K+-ATPase functioning and Na+ reabsorption[47]. 
In the second part of the present work, we took a first step in investigating the interplay 
between Na+-K+-ATPase and basolateral KATP channels in intestinal cells. Taking the previously 
mentioned aspects into account, along with the observation that dexamethasone treatment has 
been reported to increase Na+-K+-ATPase activity[8, 50, 51], we first characterized the changes in 
membrane potential of intestinal, hepatic and neuroepithelial cells exposed to drugs known to 
 block or open KATP channels. Next, we determined if pretreatment with dexamethasone associates 
with changes in membrane potential response to KATP channel blocking or opening in intestinal 
epithelial cells. Finally, we tested whether dexamethasone influences Na+-K+-ATPase protein 
expression and activity in these cells. 
  
 Materials and Methods 
 
Cell Cultures 
 Human T84 cells (ATCCâ CCL-248Ô), human HT-29 cells (ATCCâ HTB-38Ô) and human 
CACO-2 cells (ATCCâ HTB-37Ô), colonic adenocarcinoma cell lines, human SK-HEP1 cells (ATCCâ 
HTB-52Ô), a liver adenocarcinoma cell line, and human SK-N-SH cells (ATCCâ HTB-11Ô), a 
neuroblastoma-derived cell line, were obtained from the American Type Culture Collection 
(Manassas, VA) and maintained in a humidified atmosphere of 5% CO2-95% air at 37º C. T84 cells 
were grown in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 Ham (DMEM/F-12) with 
10% fetal bovine serum (Gibco 10500-064). HT-29 cells were grown in McCoy’s 5A Medium with 
10% fetal bovine serum (Gibco 10500-064). CACO-2 and SK-N-SH cells were grown in Minimum 
Essential Medium Eagle (MEM) with 10% fetal bovine serum (Gibco 10500-064). SK-HEP1 cells 
were grown in Roswell Park Memorial Institute (RPMI) 1640 Medium with 20% fetal bovine serum 
(Gibco 10500-064). All growth mediums were supplemented with 106 U/L penicillin G, 250 µg/L 
amphotericin B, 100 ng/L streptomycin (Gibco 15240-062) and 15 mM N-2-
hydroxyethylpiperazine-N’-2-ethanosulfonic acid (HEPES; Sigma H3375). Cell medium was changed 
every 2 days and cells were dissociated with 0.25% trypsin-EDTA and subcultured in 21-cm2 Petri 
dishes (Sarstedt, Germany) every 7 days. 
 
Membrane Potential 
 To characterize the effects of basolateral K+ currents and KATP channels on resting 
membrane potential in T84, HT-29, CACO-2, SK-HEP1 and SK-N-SH cells, changes in membrane 
potential were assayed after cell exposure to drugs using an anionic voltage-sensitive fluorescent 
dye, bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC4(3)), a slow-response probe which 
exhibits potential-dependent changes in cell membrane distribution accompanied by variance in 
fluorescence intensity – cell depolarization causes increased dye influx and enhanced fluorescence, 
whereas cell hyperpolarization causes dye extrusion and decreased fluorescence[52]. Used drugs 
are known to alter inwardly rectifying K+ conductance through K+ channel blocking (BaCl2) or KATP 
channel opening (pinacidil)[52, 53]. For experiments, T84, HT-29, CACO-2, SK-HEP1 and SK-N-SH 
 cells were dissociated from Petri dishes with 0.25% trypsin-EDTA, plated in 96-well plates (Sarstedt, 
Germany) and cultured as described above. After reaching confluence, cells were rinsed twice with 
Krebs assay buffer (20 mM HEPES, 120 mM NaCl, 2 mM  KCl, 2 mM CaCl2, 1 mM MgSO4 and 5 mM 
glicose; pH=7.4) containing 0.5 µM of DiBAC4(3) and incubated for 30 minutes at 37º C in order to 
ensure dye distribution cross cell membrane, as suggested by previous experiments[54]. After 
incubation, cell medium was replaced with 180 µL of Krebs assay buffer containing 0.5 µM of 
DiBAC4(3) and fluorescence was read for 15 minutes. Finally, 20 µL of test compounds (1 mM BaCl2 
and 50 µM pinacidil) were added in a 10X concentration and changes in fluorescence were 
monitored for 10 minutes. Fluorescence was measured at 488-nm excitation and 520-nm emission 
(Spectramax Gemini, Molecular Devices). 
 In a different subset of experiments, to test whether dexamethasone modulates the 
effects of basolateral K+ currents and KATP channels on resting membrane potential, T84 cells were 
pretreated with varying concentrations of dexamethasone before changes in membrane potential 
were assayed after cell exposure to BaCl2 and pinacidil. For experiments, T84 cells were dissociated 
from Petri dishes with 0.25% trypsin-EDTA, plated in Falconâ 96-well black/clear flat bottom TC-
treated microplates (Corning, USA) in 30 000 cells/well density and cultured as described above. 
Cells were treated 5 days later as confluent monolayers for 48 hours with 10-8, 10-7 and 10-6 M 
dexamethasone or vehicle (0.01% dimethyl sulfoxide – DMSO) in DMEM/F-12 medium containing 
10% fetal bovine serum, as suggested by previous studies[55]. Growth medium with or without 
dexamethasone was replaced every day. Also, as cells exposed to dexamethasone were found to 
proliferate slower than untreated cells, fetal bovine serum was present in treated and control cells 
during the whole treatment to avoid loss of cell viability[55]. Changes in membrane potential were 
then assayed as described above. 
 
In-Cell Western  
 To test whether dexamethasone influences the expression of Na+-K+-ATPase, T84 cells 
were dissociated from Petri dishes with 0.25% trypsin-EDTA, plated in Falconâ 96-well black/clear 
flat bottom TC-treated microplates (30 000 cells/well) and cultured as described above. Cells were 
treated 5 days later as confluent monolayers for 48 hours with 10-8, 10-7 and 10-6 M dexamethasone 
 or vehicle (0.01% Dimethyl Sulfoxide – DMSO) in DMEM/F-12 medium containing 10% fetal bovine 
serum. Growth medium with or without dexamethasone was  replaced every day. After treatment, 
cells were rinsed with TRIS buffered saline 1X (TBS 1X) and immediately fixed with 4% 
paraformaldehyde for 15 minutes at room temperature without shaking, as suggested by previous 
experiments[56]. Cells were then permeabilized twice with 0.05% Triton X-100 for 5 minutes and 
incubated with DyLight 800 NHS ester in phosphate-buffered saline (PBS) 1X (1:50 000 dilution; 
Life Technologies; catalog number 46422) for 20 minutes at room temperature with gentle shaking. 
After being washed thrice with PBS 1X, cells were blocked with blocking buffer (5% non-fat dry 
milk) for 1.5 hours at room temperature with gentle shaking. Cells were incubated with primary 
antibody diluted in antibody dilution buffer (2.5% non-fat dry milk) for 2 hours at room 
temperature with gentle shaking - NKAa1 Mouse Monoclonal Antibody (1:100 dilution; Santa Cruz; 
catalog number sc-21712). After being washed thrice with PBS 1X, cells were incubated with 
secondary antibody diluted in antibody dilution buffer for 1 hour at room temperature with gentle 
shaking and protected from light – Alexa Fluor 680 Goat anti-Mouse IgG (1:1000 dilution; 
Invitrogen; catalog number A-21056). Finally, after being washed thrice with PBS 1X, wells were 
imaged by scanning at 700 or 800 nm with the Odyssey CLx Infrared Imaging System (LI-COR 
Biosciences, Lincoln). Relative protein expression of Na+-K+-ATPase a1-subunit was represented by 
fluorescence intensity measured by image software (Odyssey Software Version 3.0, LI-COR 
Biosciences), normalized for DyLight 800 NHS ester-labelled proteins. 
 In a subsequent set of experiments, to test whether an increased time-exposure to 
dexamethasone affects the expression of Na+-K+-ATPase, T84 cells were dissociated from Petri 
dishes with 0.25% trypsin-EDTA, plated in Falconâ 96-well black/clear flat bottom TC-treated 
microplates (30 000 cells/well) and cultured as described above. Cells were treated 5 days later as 
confluent monolayers for 120 hours with 10-8, 10-7 and 10-6 M dexamethasone or vehicle (0.01% 
dimethyl sulfoxide – DMSO) in DMEM/F-12 medium containing 10% fetal bovine serum. Growth 
medium with or without dexamethasone was replaced every day. After treatment, protocol was 
followed as described above. Also, to test whether an increased dose-exposure to dexamethasone 
changes the expression of Na+-K+-ATPase, T84 and HT-29 cells were dissociated from Petri dishes 
with 0.25% trypsin-EDTA, plated in Falconâ 96-well black/clear flat bottom TC-treated microplates 
 (30 000 cells/well) and cultured as described above. Cells were treated 5 days later as confluent 
monolayers for 48 hours with 3 µM dexamethasone or vehicle (0.01% Dimethyl Sulfoxide – DMSO) 
in DMEM/F-12 medium or McCoy’s 5A Medium, respectively, containing 10% fetal bovine serum. 
Growth medium with or without Dexamethasone was  replaced every day. After treatment, 
protocol was followed as described above for both cell lines. 
 
Cell Viability 
 To evaluate the effect of dexamethasone treatment on T84 cell proliferation, cell viability 
was assessed using the In-Cell Western assay. DyLight 800 Amine-Reactive dye is an N-
hydroxysuccinimide (NHS) ester moiety that reacts with exposed N-terminal α-amino or ε-amino 
groups of lysine residues and is used for target protein labelling for in vitro and in vivo fluorescent 
detection strategies. For experiments, T84 cells were dissociated from Petri dishes with 0.25% 
trypsin-EDTA, plated in Falconâ 96-well black/clear flat bottom TC-treated microplates (30 000 
cells/well) and cultured as described above. Cells were treated 5 days later as confluent 
monolayers for 48 hours with 10-8, 10-7 and 10-6 M dexamethasone or vehicle (0.01% dimethyl 
sulfoxide – DMSO) in DMEM/F-12 medium containing 10% fetal bovine serum. Growth medium 
with or without dexamethasone was replaced every day. After treatment, protocol was followed 
as described above. Cell viability was assessed based on changes in DyLight 800 NHS ester-labelled 
protein expression between control and treated groups. 
 
Western Blot 
 To further investigate whether dexamethasone influences the expression of Na+-K+-
ATPase, T84 and HT-29 cells were dissociated from Petri dishes with 0.25% trypsin-EDTA, plated in 
6-well plates (Sigma-Aldrich, USA) and cultured with growth medium for 24 hours after seeding. 
For experiments, cells were then treated for 48 hours with 1 and 10 µM dexamethasone or vehicle 
(0.01% dimethyl sulfoxide – DMSO) in growth medium containing 10% fetal bovine serum and 
further kept in growth medium for 24 hours in order to reach confluence. After treatment, cells 
were rinsed twice with TBS 1X and exposed to RIPA Lysis Buffer (150 mM NaCl, 50 mM Tris-HCl 
pH=7.4, 5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS) containing 
 protease inhibitors (1 mM PMSF, 1 µL/mL of aprotinin and 1 µL/mL of leupeptin) and phosphatase 
inhibitors (5 mM Na3VO4 and 5 mM NaF). Cells were scraped from 6-well plates, lysed by sonication 
(40 Hz; 10 seconds) and incubated on ice for 30 minutes, in order to obtain total protein extraction. 
After centrifugation (13 200 g for 30 minutes at 4º C), the supernatants were collected and the 
amount of protein was quantified using the method of Bradford (Bio-Rad). Proteins (30 µg) were 
warmed at 70º C for 10 minutes, separated on a 7.5% SDS-polyacrylamide (2 hours; 140 mV) and 
electrotransfered to nitrocellulose membranes. Membranes were blocked in blocking buffer (5% 
non-fat dry milk) for 1 hour at room temperature with gentle shaking. After being washed with 
TBS-T, membranes were incubated overnight with primary antibodies diluted in antibody dilution 
buffer (2.5% non-fat dry milk) at 4º C – NKAa1 Mouse Monoclonal Antibody (1:1000 dilution; Santa 
Cruz; catalog number sc-21712) and GAPDH Mouse Monoclonal Antibody (1:20 000 dilution; Santa 
Cruz; catalog number sc-32233). After being washed four times with TBS-T, membranes were 
incubated with secondary antibody diluted in antibody dilution buffer for 1 hour at room 
temperature with gentle shaking and protection from light – Alexa Fluor 680 Goat anti-Mouse IgG 
(1:1000 dilution; Invitrogen; catalog number A-21056). Finally, after being washed four times with 
TBS-T and once with TBS, membranes were imaged by scanning at 700 or 800 nm with the Odyssey 
CLx Infrared Imaging System (LI-COR Biosciences, Lincoln). Relative abundance of Na+-K+-ATPase 
a1-subunit was represented by fluorescence intensity measured by image software (Odyssey 
Software Version 3.0, LI-COR Biosciences), normalized for GAPDH. 
 
Fluorometric Assay 
 To investigate whether dexamethasone influences Na+-K+-ATPase activity, T84 cells were 
plated in 21-cm2 Petri dishes (Sarstedt, Germany) and cultured as described above until 2 days 
after reaching confluence. For experiments, cells were treated for 48 hours with 10-6 M 
dexamethasone or vehicle (0.01% dimethyl sulfoxide – DMSO) in DMEM/F-12 medium containing 
10% fetal bovine serum. Growth medium with or without dexamethasone was replaced every day. 
Cells were then detached with 0.25% trypsin-EDTA and resuspended in Buffer A (10 nM HEPES and 
250 mM sucrose; ph=7.4) containing protease inhibitors (0.2 µL/mL of aprotinin and 0.2 µL/mL of 
leupeptin), lysed by sonication (40 Hz; 10 seconds) and incubated at 30º C for 10 minutes with 0.3 
 mg/mL sodium dodecyl sulfate (SDS) in order to obtain total protein extraction. Next, cell lysates 
were resuspended in Buffer A and the amount of protein was quantified using the method of 
Bradford (Bio-Rad). The activity of Na+-K+-ATPase was then measured by fluorometric method 
using 3-O-methylfluorescein phosphate (3-O-MFP). This compound is a substrate for the 
phosphatase reaction catalyzed by Na+-K+-ATPase and a precursor of the fluorescent compound 3-
O-methylfluorescein (3-O-MF), thereby exhibiting Na+-K+-ATPase activity-dependent variance in 
fluorescence intensity – higher NKA activity results in increased cleavage of the phosphate group 
from 3-O-MFP and formation of 3-O-MF, thus enhancing fluorescence emission[57, 58]. As 
suggested by previous reports[58], the experiment was performed in assay medium containing 5 
mM creatine phosphate, 4 mM MgCl2, 0.5 mM EGTA, 80 mM Tris-HCl and 50 µM 3-O-MFP. Baseline 
fluorescence was assessed for 60 seconds, before 10 µL of cell lysates (~1 mg of protein) were 
added and fluorescence was recorded over a 140-second period. Then, 10 µL of 2 M KCl (final 
concentration of 10 mM) were added to activate Na+-K+-ATPase and fluorescence was monitored 
for additional 200 seconds. Finally, experiments were repeated for assay medium containing 5 mM 
ouabain. As K+ is necessary for pump activation and ouabain is a known inhibitor of ATP-dependent 
sodium potassium exchange[58, 59], the activity of Na+-K+-ATPase was calculated as the slope 
difference in fluorescence recordings before and after addition of K+, with and without ouabain in 
the buffer. These values were then related to protein content of cell lysates and final expression 
of activity was given as nanomoles of liberated phosphate per milligram of protein per minute 
(nmol Pi/mg/min). Fluorescence was measured at 470-nm excitation and 510-nm emission 
(FluoroMax-2, Jobin Yvon-Spex Instruments). 
 
Data Analysis 
 Arithmetic means are given with standard deviation and geometrical means are given 
with 95% confidence values. Statistical analysis was performed using One-Way analysis of variance 
(ANOVA), followed by Student’s t test or Newman-Keuls test for multiple comparisons in GraphPad 
Prism (GraphPad Software, San Diego). A P-value<0.05 was assumed to denote a significant 
difference. Graphs were prepared using GraphPad Prism (GraphPad Software, San Diego) and error 
bars depict SEM unless otherwise noted. 
 Drugs 
 BaCl2 and KCl were obtained from Merk (Darmstadt, Germany). Pinacidil, dexamethasone, 
ouabain and DMEM/F-12, McCoy’s 5A, MEM and RPMI 1640 mediums were purchased from 
Sigma-Aldrich (St. Louis, USA). Fetal bovine serum and antibiotic were obtained from Thermo 
Fisher Scientific (California, USA). 
  
 Results 
 
Effects of basolateral K+ currents and KATP channels on resting membrane potential in human 
T84, HT-29, CACO-2, SK-HEP1 and SK-N-SH cells 
 To characterize how modification of basolateral K+ conductance affects resting membrane 
potential, we used the voltage-sensitive dye DiBAC4(3) to assess changes in membrane potential 
in human T84, HT-29, CACO-2, SK-HEP1 and SK-N-SH cells following the application of drugs that 
inhibit or stimulate these ionic currents through ATP-sensitive K+ (KATP) channels. Results are shown 
in Figure 1. We observed an increase in DiBAC4(3) fluorescence after exposure of T84 cells to 1 mM 
Ba2+, indicating a depolarization (Figure 1A). Conversely, fluorescence intensity decreased after 
exposure of T84 cells to 50 µM pinacidil, indicating a hyperpolarization (Figure 1A). This pattern of 
T84 cell depolarization and hyperpolarization following application of 1 mM BaCl and 50 µM 
pinacidil, respectively, was similar to the pattern observed in HT-29, CACO-2, SK-HEP1 and SK-N-
SH cells under the same experimental conditions (Figure 1, B-E). 
 
Effects of dexamethasone on basolateral K+ currents and KATP channels in human T84 cells 
 To assess whether dexamethasone modulates the effects of basolateral K+ currents and 
KATP channels on resting membrane potential, human T84 cells were pretreated for 48 hours with 
varying concentrations of dexamethasone (10-8, 10-7 and 10-6 M) and changes in cell membrane 
potential after treatment with BaCl2 and pinacidil were monitored with the use of fluorescent dye 
DiBAC4(3). Results are shown in Figure 2. In control group, mean change in fluorescence after 
treatment with 1 mM BaCl2 and 50 µM pinacidil was 549.5 ± 50.13 (95% confidence interval of 
451.2 to 647.8) and -63.56 ± 35.45 (95% confidence interval of 0 to -133), respectively. In 10-8 M 
dexamethasone treatment group, mean change in fluorescence after treatment with 1 mM BaCl2 
and 50 µM pinacidil was 695.1 ± 28.03 (95% confidence interval of 640.2 to 750) and -3.183 ± 2.092 
(95% confidence interval of 0 to -7.283), respectively. In 10-7 M dexamethasone treatment group, 
mean change in fluorescence after treatment with 1 mM BaCl2 and 50 µM pinacidil was 427.8 ± 
28.79 (95% confidence interval of 371.4 to 484.3) and -207 ± 13.5 (95% confidence interval of -
180.6 to -233.5), respectively. In 10-6 M dexamethasone treatment group, mean change in 
 fluorescence after treatment with 1 mM BaCl2 and 50 µM pinacidil was 352 ± 45.43 (95% 
confidence interval of 264 to 442) and -346 ± 25.55 (95% confidence interval of -296.3 to -396.5), 
respectively. Treatment with 10-7 and  10-6 M dexamethasone led to a significant reduction in 
DiBAC4(3) fluorescence after exposure of T84 cells to 1 mM BaCl2 and 50 µM pinacidil, indicating a 
decreased depolarization response to KATP channel blocking (mean differences in fluorescence 
emission of -121.7 ± 19.67 and -196.5 ± 19.67, respectively) and an increased hyperpolarization 
response to KATP channel opening (mean differences in fluorescence emission of -143.4 ± 11.45 and 
-282.8 ± 11.45, respectively). However, at minimal concentrations (10-8 M), dexamethasone 
treatment leads to a significant rise in DiBAC4(3) fluorescence after exposure of T84 cells to 1 mM 
BaCl2 and 50 µM pinacidil, indicating an increased depolarization response to KATP channel blocking 
(mean difference in fluorescence emission of 145.6 ± 19.67) and an decreased hyperpolarization 
response to KATP channel opening (mean difference in fluorescence emission of 60.38 ± 11.45).  
 
Effects of dexamethasone on Na+-K+-ATPase protein expression and cell viability in human T84 
and HT-29 cells 
To examine whether the dexamethasone-induced modulation of basolateral K+ 
conductance is mediated by altered Na+-K+-ATPase protein expression, human T84 cells were 
exposed for 48 hours to varying concentrations of dexamethasone (10-8, 10-7 and 10-6 M) and 
subjected to In-Cell Western analysis to evaluate changes in Na+-K+-ATPase a1-subunit abundance. 
Results are shown in Figure 3A – for 48-hour exposure, mean protein expression in the control, 10-
8, 10-7 and 10-6 M dexamethasone treatment groups was 0.1072 ± 0.01918 (95% confidence 
interval of 0.1232 to 0.09112), 0.1049 ± 0.01571 (95% confidence interval of 0.118 to 0.09176), 
0.1256 ± 0.02237 (95% confidence interval of 0.1443 to 0.1069) and 0.1108 ± 0.0185 (95% 
confidence interval of 0.1263 to 0.09537), respectively. The relative abundance of Na+-K+-ATPase 
was not significantly altered following treatment. Alongside, the effects of dexamethasone on T84 
cell proliferation were also evaluated. As depicted in Figure 4, T84 cell proliferation was not 
significantly affected by 10-8, 10-7 and 10-6 M dexamethasone exposure – 93.83 ± 7.584% of control, 
84.09 ± 7.584% of control and 86.67 ± 7.584% of control, respectively. 
 To test whether an increased time-exposure to dexamethasone induces a different 
response in Na+-K+-ATPase protein expression, human T84 cells were exposed for 120 hours to the 
same concentrations of dexamethasone (10-8, 10-7 and 10-6 M) and subjected to In-Cell Western 
analysis to evaluate changes in Na+-K+-ATPase a1-subunit protein abundance. Results are shown 
in Figure 3B – for 120-hour exposure, mean relative protein expression in the control, 10-8 M, 10-7 
M and 10-6 M dexamethasone treatment groups was 0.085 ± 0.01077 (95% confidence interval of 
0.094 to 0.076), 0.097 ± 0.01254 (95% confidence interval of 0.1075 to 0.08652), 0.1011 ± 0.02231 
(95% confidence interval of 0.1198 to 0.08248) and 0.09013 ± 0.01229 (95% confidence interval of 
0.1004 to 0.07985), respectively. The relative abundance of Na+-K+-ATPase was not significantly 
altered following treatment. 
To test whether an increased dose-exposure to dexamethasone causes a change in Na+-
K+-ATPase protein expression, human T84 and HT-29 cells were exposed for 48 hours with 3 µM 
dexamethasone and subjected to In-Cell Western analysis to evaluate changes in Na+-K+-ATPase 
a1-subunit protein abundance. Results are shown in Figure 5. For T84 cells, mean relative protein 
expression in the control and treatment groups was 5.015 ± 0.5805 (95% confidence interval of 
4.53 to 5.501) and 6.506 ± 0.5533 (95% confidence interval of 6.044 to 6.969), respectively (Figure 
5A). For HT-29 cells, mean relative protein expression in the control and treatment groups was 
4.955 ± 1.423 (95% confidence interval of 3.765 to 6.114) and 6.955 ± 1.765 (95% confidence 
interval of 5.48 to 8.431), respectively (Figure 5B). The relative abundance of Na+-K+-ATPase was 
significantly higher following treatment (mean difference of 1.491 ± 0.2835 and 2 ± 0.8015, 
respectively). 
Human T84 and HT-29 cells were also subjected to Western Blot analysis to further test 
whether higher concentrations of dexamethasone (1 and 10 µM) elicit an increase in Na+-K+-
ATPase a1-subunit protein abundance during a 48-hour treatment. Results are shown in Figure 6. 
For T84 cells, mean relative protein expression in the control, 1 and 10 µM dexamethasone 
treatment groups was 0.2655 ± 0.005931 (95% confidence interval of 0.2122 to 0.3188), 0.2373 ± 
0.009395 (95% confidence interval of 0.1529 to 0.3217) and 0.2905 ± 0.0007128 (95% confidence 
interval of 0.2841 to 0.2969), respectively (Figure 6A). For HT-29 cells, mean relative protein 
 expression in the control, 1 and 10 µM dexamethasone treatment groups was 0.05154 ± 0.007813 
(95% confidence interval of -0.01866 to 0.1217), 0.03545 ± 0.001595 (95% confidence interval of 
0.02113 to 0.04978),and 0.09755 ± 0.01479 (95% confidence interval of -0.03532 to 0.2304), 
respectively (Figure 6B). As shown, 48-hour treatment with 10 µM dexamethasone prompts an 
upregulation of Na+-K+-ATPase in T84 cells (mean difference of 0.02503 ± 0.006428), with 
consistent findings for HT-29 cells (mean difference of 0.04602 ± 0.009701). 
 
Effects of dexamethasone on Na+-K+-ATPase activity in human T84 cells 
 To verify whether dexamethasone regulates the activity of Na+-K+-ATPase, human T84 
cells were exposed for 48 hours to 10-6 M dexamethasone and subjected to fluorometric assay 
using 3-O-methylfluorescein phosphate (3-O-MFP) to measure NKA activity. We considered the 
slope difference in fluorescence recordings before and after addition of K+ to assay medium, with 
and without ouabain in the buffer, as an indirect measure of NKA activity, which was related to 
protein content of cell lysates and thus converted to nanomoles of liberated phosphate per 
milligram of protein per minute (nmol Pi/mg/min). Results are shown in Figure 7. Mean Na+-K+-
ATPase activity in the control and treatment groups was 12.50 ± 1.578 (95% confidence interval of 
11.38 to 13.61) and 14.92 ± 3.530 (95% confidence interval of 12.42 to 17.41), respectively. Mean 
Na+-K+-ATPase activity was slightly higher following treatment (mean difference of 2.423 ± 2.734). 
  
 Discussion 
The aim of present experimental study was to investigate the functional interplay 
between Na+-K+-ATPase activity and basolateral K+ channel activity in intestinal cells, a core 
mechanism in sodium uptake extensively considered in renal proximal tubule models. In our 
results, a modulation of basolateral K+ conductance has been observed after incubation of human 
T84 cells with low concentrations of dexamethasone (10-7 and 10-6 M) without accompanying 
increases in Na+-K+-ATPase protein expression. Increased Na+-K+-ATPase activity was also seen in 
these cells following treatment. These effect are in agreement with the view that dexamethasone-
induced stimulation of Na+-K+-ATPase activity associates with an increased basolateral K+ channel 
activity as a result of the pump-leak coupling mechanism required for continued transcellular 
sodium absorption. Furthermore, our results show for the first time that higher concentrations of 
dexamethasone (3 and 10 µM) produce an upregulation of Na+-K+-ATPase in intestinal cells. 
We first started to characterize how modification of basolateral K+ conductance through 
ATP-sensitive K+ (KATP) channels affects resting membrane potential in different intestinal and non-
intestinal cell lines. KATP channel activity has been demonstrated to be dependent of intracellular 
nucleotides: low intracellular ATP levels disinhibit KATP channels, resulting in increased basolateral 
K+ conductance and membrane hyperpolarization[48, 49]. As barium (Ba2+) is a inwardly rectifying 
potassium (Kir) channel blocker and pinacidil is a KATP channel opener, we expected a change in cell 
membrane potential in the presence of these compounds[52, 53]. Using the voltage-sensitive dye 
DiBAC4(3), our results demonstrate that altering basolateral K+ conductance through ATP-sensitive 
K+ (KATP) channels can lead to changes in cell membrane potential in T84, HT-29, CACO-2, SK-HEP1 
and SK-N-SH cells; KATP channel blocking by BaCl2 causes cell depolarization, whereas KATP channel 
opening by pinacidil causes cell hyperpolarization. 
 In a second set of experiments, we explored the relationship between KATP channels and 
cellular metabolism secondary to Na+-K+-ATPase activity in intestinal cells. It is well established in 
renal proximal tubule cells that coordination between Na+-K+-ATPase activity and basolateral K+ 
channel conductance (pump-leak coupling) is an important functional mechanism for cell volume 
and homeostasis during epithelial transport[45]. Stimulation of NKA activity leads to increased K+ 
conductance, which appears to result from the opening of KATP channels in the basolateral 
 membrane after local reductions in ATP levels[60]. It has been recognized that dexamethasone 
enhances Na+-K+-ATPase activity[8, 50, 51]. Using the DiBAC4(3) probe, we demonstrate that 48-
hour dexamethasone pretreatment causes a concentration-dependent modulation of basolateral 
K+ conductance and KATP channels activity in T84 cells, thus leading to significant changes in 
membrane potential response after exposure to BaCl2 and pinacidil. Dexamethasone promoted a 
decreased depolarization response to KATP channel blocking and an increased hyperpolarization 
response to KATP channel opening at concentrations of 10-7 and 10-6 M, but not at 10-8 M. Besides 
increasing basolateral ATP-sensitive K+ conductance, higher NKA activity in intestinal cells may 
directly affect resting membrane potential, resulting in membrane hyperpolarization[47]. By 
applying a depolarizing or hyperpolarizing stimulus in a progressively hyperpolarized membrane, 
KATP channel blocking results in progressively smaller overshoots and KATP channel opening results 
in progressively larger undershoots. Since the primary role of KATP channels is to allow recycling of 
K+ pumped into the cell by Na+-K+-ATPase, mediating hyperpolarization of the basolateral 
membrane[45], these results suggest the interpretation that dexamethasone-induced changes in 
basolateral K+ currents and KATP channel activity may be secondary to increased Na+-K+-ATPase 
activity. 
 As an increased Na+-K+-ATPase activity can reflect either an upregulation of this enzyme 
or a boosted catalytic activity of the NKA units present at the plasma membrane, we first tested 
whether the dexamethasone-induced modulation of basolateral K+ currents was mediated by 
increased Na+-K+-ATPase protein expression. Using the In-Cell Western analysis, our results showed 
no significant increase in Na+-K+-ATPase abundance in T84 cells under the same experimental 
conditions. Later, we verified whether dexamethasone regulates NKA activity at concentrations 
associated with peak effects in basolateral K+ conductance modulation. Using the 3-O-
methylfluorescein phosphate (3-O-MFP) fluorometric assay, a rise in Na+-K+-ATPase activity was 
observed in T84 cells treated with 10-6 M dexamethasone. Therefore, we demonstrate that 
dexamethasone produces changes in basolateral ATP-sensitive K+ conductance that are 
independent of Na+-K+-ATPase upregulation and most likely attributable to increased NKA activity. 
However, since Dexamethasone is known to induce a number of cellular changes in cultured 
human cells in a time- and concentration-dependent fashion, we cannot exclude the possibility 
 that other ion transport mechanisms such as sodium-potassium-chloride (Na-K-Cl) 
cotransporter[55],  chloride (Cl-) channels[61], potassium (K+) channels[62] and sodium-potassium 
(Na/K) antiporter [63] could also be affected and thus be relevant for the corticoid-induced 
modulation of basolateral K+ currents. Hence, future experiments using the Ussing Chamber 
Technique to measure the effects of dexamethasone on Na+-K+-ATPase activity and basolateral 
membrane K+ conductance would provide more accurate information on the contribution of other 
intestinal ion transporter systems. 
In a subsequent set of experiments, we wanted to investigate whether an increased time- 
and dose-exposure to dexamethasone would induce changes in Na+-K+-ATPase expression. Using 
In-Cell Western analysis, our results did not show significant differences in NKA abundance in T84 
cells exposed to 10-8 M, 10-7 M and 10-6 M dexamethasone after extending the treatment period 
to 120 hours. On the other hand, a significant rise in NKA protein expression was seen in T84 cells 
treated for 48 hours with 3 µM dexamethasone. In fact, the same upregulating response was 
observed in HT-29 cells, an additional intestinal epithelial cell line. Moreover, by using a different 
method for protein quantification in Western Blot, we also confirmed a dexamethasone-induced 
sodium pump overexpression in T84 and HT-29 cells at an even higher concentration of 
dexamethasone (10 µM). 
Taken together, our results are in agreement with the view that dexamethasone 
treatment leads to a concentration-dependent modulation of basolateral K+ currents that is 
independent of Na+-K+-ATPase protein overexpression and most likely secondary to increased NKA 
activity, as a result of the functional coupling between Na+-K+-ATPase and basolateral KATP channels 
present in intestinal cells. Furthermore, we also report for the first time that dexamethasone can 
induce an upregulation of Na+-K+-ATPase in intestinal epithelial cells at higher treatment 
concentrations. 
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 Figure 1. Effects of basolateral K+ currents and KATP channels on resting membrane potential in 
human T84 (A), HT-29 (B), CACO-2 (C), SK-HEP1 (D) and SK-N-SH cells (E). Plotted symbols show 
values for the average of cells (n=8 for A-B; n=4 for D-E). Traces and summarized data (area under 
the curve) show time course-dependent changes in DiBAC4(3) fluorescence emission after cell 
exposure to 1 mM BaCl2 and 50 µM pinacidil, indicating that KATP channel blocking by Ba2+ leads to 
cell depolarization, whereas KATP channel opening by pinacidil leads to cell hyperpolarization in all 
tested cell lines. Fluorescence was read for 10 minutes and assay buffer contained 0.5 µM 
DiBAC4(3) in all experiments. 
  
    
 
Figure 2. Concentration-dependent effects of dexamethasone on basolateral K+ currents and KATP 
channels in human T84 cells. Summarized data shows changes in DiBAC4(3) fluorescence emission 
after exposure of T84 cells pretreated for 48 hours with varying concentrations of dexamethasone 
or vehicle to 1 mM BaCl2 (A) and 50 µM pinacidil (B). Columns show mean values and vertical lines 
indicate SEM (n=8). Treatment with 10-8 M dexamethasone leads to increased depolarization 
response to KATP channel blocking and decreased hyperpolarization response to KATP channel 
opening, whereas treatment with 10-7 and  10-6 M dexamethasone leads to decreased 
depolarization response to KATP channel blocking and increased hyperpolarization response to KATP 
channel opening. 
****Significant differences from control group (P-value<0.0001). 
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Figure 3. Effects of dexamethasone on Na+-K+-ATPase protein expression in human T84 cells. 
Relative abundance of Na+-K+-ATPase a1-subunit in T84 cells treated for 48 hours (A) and 120 hours 
(B) with varying concentrations of dexamethasone or vehicle, determined by In-Cell Western 
analysis. Columns show mean values and vertical lines indicate SEM (n=8). Protein expression was 
normalized for DyLight 800 NHS ester-labelled proteins. Treatment for 48 and 120 hours with 10-
8, 10-7 and 10-6 M dexamethasone does not show significant differences in Na+-K+-ATPase a1-
subunit expression in T84 and HT-29 cells. 
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Figure 4. Effects of dexamethasone on human T84 cell viability. Summarized graphics show 
percentage abundance of DyLight 800 NHS ester-labelled proteins in T84 cells treated for 48 hours 
with varying concentrations of dexamethasone in relation to control, determined by In-Cell 
Western analysis. Columns show mean values and vertical lines indicate SEM (n=8). Treatment for 
48 hours with 10-8, 10-7 and 10-6 M dexamethasone does not show significant differences in T84 
cell proliferation. 
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Figure 5. Effects of dexamethasone on Na+-K+-ATPase protein expression in human T84 and HT-29 
cells. Relative abundance of Na+-K+-ATPase a1-subunit in T84 (A) and HT-29 cells (B) treated for 48 
hours with 3 µM dexamethasone or vehicle, determined by In-Cell Western analysis. Columns 
show mean values and vertical lines indicate SEM (n=8). Protein expression was normalized for 
DyLight 800 NHS ester-labelled proteins. Treatment for 48 hours with 3 µM dexamethasone leads 
to a significant upregulation of Na+-K+-ATPase a1-subunit expression in T84 and HT-29 cells. 
* Significant differences from control group (P-value<0.05). 
*** Significant differences from control group (P-value<0.005). 
  
Control 3 µM
0
2
4
6
8
10
[Dexamethasone]
α
1-
su
bu
ni
t N
a+
-K
+ -
AT
Pa
se
(re
la
tiv
e 
pr
ot
ei
n 
ex
pr
es
si
on
)
T-84 cells
***
Control 3 µM
0
2
4
6
8
10
[Dexamethasone]
α
1-
su
bu
ni
t N
a+
-K
+ -
AT
Pa
se
(re
la
tiv
e 
pr
ot
ei
n 
ex
pr
es
si
on
)
HT-29 cells
*
Control 1 µM 10 µM
0.0
0.1
0.2
0.3
0.4
[Dexamethasone]
α
1-
su
bu
ni
t N
a+
-K
+ -
AT
Pa
se
 / 
G
A
PD
H
(re
la
tiv
e 
pr
ot
ei
n 
ex
pr
es
si
on
)
T-84 cells
Control 1 µM 10 µM
0.0
0.1
0.2
0.3
0.4
[Dexamethasone]
α
1-
su
bu
ni
t N
a+
-K
+ -
AT
Pa
se
 / 
G
A
PD
H
(re
la
tiv
e 
pr
ot
ei
n 
ex
pr
es
si
on
)
HT-29 cells
A
B
A
B
  
 
Figure 6. Effects of dexamethasone on Na+-K+-ATPase protein expression in human T84 and HT-29 
cells. Relative abundance of Na+-K+-ATPase a1-subunit in T84 (A) and HT-29 cells (B) treated for 48 
hours with 1 and 10 µM dexamethasone or vehicle, determined by Western Blot analysis. Columns 
show mean values and vertical lines indicate SEM (n=2). Protein expression was normalized for 
GAPDH. Treatment for 48 hours with 10 µM dexamethasone leads to upregulation of Na+-K+-
ATPase a1-subunit expression in T84 and HT-29 cells.  
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Figure 7. Effects of dexamethasone on Na+-K+-ATPase activity in human T84 cells. Summarized data 
shows the ouabain-sensitive NKA activity in T84 cells pretreated for 48 hours with 10-6 M 
dexamethasone, determined by the 3-O-MFP fluorometric method. Columns show mean values 
and vertical lines indicate SEM (n=2). Treatment with 10-6 M dexamethasone leads to increased 
Na+-K+-ATPase activity in T84 cells. 
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 General Discussion 
Despite being a multifactorial and polygenetic condition strongly associated to high salt 
intake, the pathogenesis of hypertension remains obscure and requests for continued research on 
behalf of better understanding of the disease and development of new therapeutic strategies[34, 
35, 40]. Recently, salt-inducible kinase 1 (SIK1) has been recognized as an important factor in blood 
pressure regulation via modulation of Na+-K+-ATPase (NKA) activity under sodium stress 
conditions[6]. In particular, changes in renal and vascular SIK1 and NKA activities have been 
described in association with the development of salt-sensitive hypertension[35, 39]. On the other 
hand, the gastrointestinal tract has also been suggested as a core element in the regulation of 
cardiometabolic homeostasis, since excessive intestinal sodium uptake is recognized to encourage 
the development of hypertension[40]. Regarding these aspects, we hypothesized that SIK1 activity 
present in other tissues such as the gastrointestinal tract might represent an alternative salt-
inducible mechanism for blood pressure regulation under chronic high salt intake, rendering a 
promising target for the comprehension and management of hypertension. 
The present work further studied the role of SIK1 in sodium-sensible hypertension 
development in two sections. In Part I, we have characterized the effects of SIK1 ablation on blood 
pressure, focusing on renal and sympathetic nervous system mechanisms of salt-induced 
hypertension. In Part II, we took a first step in investigating the involvement of intestinal SIK1 
activity in blood pressure regulation, focusing on the characterization of intestinal ion transport 
mechanisms that are potentially subject to SIK1 regulation. As described in our experimental study, 
the observed dexamethasone-induced modulation of basolateral K+ currents, along with its effects 
on the regulation of Na+-K+-ATPase protein expression and activity, suggest a potential interplay 
between Na+-K+-ATPase and KATP channels in intestinal cells. As described in renal proximal tubule 
experimental models, this functional coupling between Na+-K+-ATPase activity and basolateral K+ 
channel activity (pump-leak) is mediated by KATP channels and is of prime importance for epithelial 
ion transport – in fact, Na+-K+-ATPase activity regulation induces adjustments in basolateral KATP 
channel activity to the same extent as adjustments in basolateral KATP channel activity are required 
for Na+-K+-ATPase activity regulation[45]. 
 Salt-inducible kinase 1 is known to affect the catalytic properties of the Na+-K+-ATPase 
units present at the plasma membrane by enhancing their activity in response to elevated 
intracellular sodium without interfering with NKA recruitment[6]. Since intestinal Na+-K+-ATPase 
activity dysregulation and abnormal sodium homeostasis also comprise key molecular mechanisms 
responsible for blood pressure rise under chronic high salt intake, we believe it is valuable to 
evaluate the role of SIK1 in intestinal sodium transport mechanisms, in particular the pump-leak 
coupling between Na+-K+-ATPase and KATP channels. Future investigations with cells transiently or 
stably lacking SIK1 using siRNA or shRNA and in vivo studies with sik1-/- mice are needed for better 
comprehension of the underlying physiologic mechanisms and to assess whether SIK1 blocking 
affects sodium balance and blood pressure through intestinal mechanisms. 
  
